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ABSTRACT
This dissertation is comprised of two manuscripts which examine the longitudinal
development of autism symptomatology in young children at risk for developing autism
spectrum disorder (ASD); individuals with Fragile x syndrome (FXS) and Down
syndrome (DS). The first study is a within group analysis of the longitudinal development
of ASD symptomatology in young children with FXS, and how diagnostic stability,
language and non-verbal cognitive functioning may predict these trajectories. This paper
provides insight into ASD diagnostic stability patterns within FXS, and how symptoms
change over time across these groups. The second paper will extend this work by
presenting a pilot cross-syndrome comparison, which includes young children with FXS,
DS and non-syndromic ASD to examine hypothesis of unique ASD symptom trajectories
between the disorders. This pilot examination will set the stage for future larger scale
cross syndrome comparisons to target these important questions. Together, the findings
presented here inform the theoretical understanding of ASD within FXS, as well as
support clinical recommendations for screening, monitoring and diagnosing ASD within
FXS.
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CHAPTER 1
PREDICTING CHANGE IN AUTISM SYMPTOMATOLOGY IN YOUNG
CHILDREN WITH FRAGILE X SYNDROME
Autism Spectrum Disorder (ASD) is a behaviorally defined disorder characterized
by core impairments in social communication and the presence of atypical restricted
interests and repetitive behaviors (American Psychiatric Asssociation, 2013). ASD is a
heterogeneous disorder, with cognitive, language and adaptive impairments ranging
significantly between individuals. This significant heterogeneity has led the field to shift
focus to the identification of possible distinct phenotypes within the autism spectrum,
labeled the “autisms” by some (Geschwind & Levitt, 2007). Early work aimed at
identifying mechanisms targeted genetic factors given the established heritability present
in twin studies (Geschwind, 2011). However, genetic biomarkers underlying ASD are
complicated with the identification of over 1000 potential risk genes (Vorstman et al.,
2013), and at least 4 single gene disorders with significant relationships to ASD
(Geschwind, 2011).
Fragile X syndrome (FXS) has the highest penetrance of any single gene disorder
implicated in ASD, with between 60-75% of individuals meeting criteria for ASD (Harris
et al., 2008; Klusek, Martin, & Losh, 2014) and upwards of 90% exhibiting at least one
symptom (Bailey, Hatton, Mesibov, Ament, & Skinner, 2000). Males with FXS and ASD
also exhibit a more homogenous behavioral phenotype (e.g. intellectual disability,
language delay) than individuals with non-syndromic ASD (nsASD), making it an ideal
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model for the study of the development of ASD. By examining a more homogenous
group of individuals with ASD, targeted treatments, similar to the precision medicine
approach in the physical health field, may be achieved.
FXS is caused by an expansion on the FMR1 gene of the CGG repeat sequence on
the X chromosome. In the typical population, average CCG repeat length is less than 55,
with expansions of 55-200 repeats considered the fragile X premutation. When the
expansion exceeds 200 repeats, a reduction in Fragile X Mental Retardation Protein
(FMRP) ensues. FMRP is essential for cognitive development (Garber, Visootsak, &
Warren, 2008). Males and females with FXS are differentially impacted by the disorder
given the protective factor afforded to females by the presence of a second, typically
unaffected, X chromosome. Therefore, females with FXS are often less severely impaired
across a range of domains than males (Hagerman & Hagerman, 2002).
Autism Features in FXS
Core features of ASD including social impairments and restricted and repetitive
behaviors are generally accepted as common behavioral features in FXS, however
questions remain as to the whether or not these features may occur on a spectrum within
individuals with FXS or if they represent a true comorbidity of ASD. These questions
have been part of an ongoing discussion in the literature for the last 30 years in an
attempt to explain the elevated proportion of males with FXS and ASD. Initial theories to
explain the elevated features of ASD in FXS (Cohen et al., 1991) proposed possible
pathways driven by biological markers of FXS (e.g. FMRP) or secondary consequences
of almost universal intellectual disability. Recent work has sought to provide clarity on
this issue by directly testing these relationships. Hall and colleagues examined the
2

relationships between parent reported autism symptoms and biological markers (i.e.
FMRP) and cognitive functioning in a sample of 120 individuals with FXS 5-25 years of
age. Cognitive functioning, but not FMRP, was related to autism symptomatology with
lower cognitive functioning associated with greater parent reported autism
symptomatology (Hall, Lightbody, Hirt, Rezvani, & Reiss, 2010). The null relationship
between FMRP and autism symptomatology is consistent with previous work reporting
similar findings (Donald B Bailey Jr, Hatton, Skinner, & Mesibov, 2001; Rogers,
Wehner, & Hagerman, 2001).
Others have approached the question of unique and shared ASD features in FXS
and non-syndromic ASD through a comparative behavioral lens. This approach explores
whether behavioral features across individuals with nsASD and FXS with comorbid
autism (FXS+ASD) are parallel, which would provide evidence that ASD in both groups
could arise from a similar etiology. Findings from this body of work suggest a
developmental effect in which autism symptomatology is remarkably similar between 2148 month olds with FXS+ASD and nsASD (Rogers et al., 2001), with a unique
behavioral phenotype of strengths in the quality and frequency of social overtures in
those with FXS+ASD, that is not seen in nsASD, becoming evident over time (McDuffie,
Thurman, Hagerman, & Abbeduto, 2014; Wolff et al., 2012). These findings have led
some researchers to hypothesize that the features of ASD seen in FXS do not arise from
the same mechanistic underpinnings (Abbeduto, McDuffie, & Thurman, 2014; Hall et al.,
2010). This is supported by evidence of structural brain abnormalities in young children
with nsASD that differ from those with FXS+ASD despite similar behavioral features of
ASD across the two groups (Hazlett et al., 2009).
3

Despite possible mechanistic differences giving rise to shared features of ASD
across groups, consistency exists in findings that individuals with FXS+ASD are more
impaired across a range of domains that those with FXS without ASD (FXS-noASD)
including cognition (Bailey, Hatton, Tassone, Skinner, & Taylor, 2001; Hogan et al.,
2017; Kaufmann et al., 2004), adaptive behavior (Caravella & Roberts, 2017; Hahn,
Brady, Warren, & Fleming, 2015), language (Klusek et al., 2014), motor skills (Bailey et
al., 2000) and social approach behaviors (Roberts, Weisenfeld, Hatton, Heath, &
Kaufmann, 2007). Additionally, children with FXS+ASD receive more hours of speechlanguage and behavioral therapy than those without an ASD diagnosis (Martin et al.,
2013). Therefore, identifying ASD features in FXS is essential for providing access to the
appropriate dose and type of intervention required to reduce functional impairment.
Identifying predictors of ASD in young children with FXS is essential towards efforts to
improve treatment with several features emerging as salient. Sex is one of the most wellestablished predictors of ASD in FXS, with males being significantly more likely to show
impairing symptoms of ASD as well as meet diagnostic criteria (Hall et al., 2010; Klusek
et al., 2014). Cognitive level and language ability have also been identified to predict
autism symptomatology in FXS beginning in infancy (Hogan et al., 2017) and
maintaining through childhood and early adolescence (Klusek et al., 2014). Greater
pragmatic language impairments have also been found as predictors of increased autism
symptom severity (Lee, Martin, Berry-Kravis, & Losh, 2016).
Stability of Autism Symptomatology in nsASD and FXS
Stability of a positive ASD diagnosis in non-syndromic populations has been
reported to be between 53-100% (Woolfenden, Sarkozy, Ridley, & Williams, 2012). In
4

community samples, autism is generally stable (~90%) by 2 years of age when using a
clinical best estimate (CBE) procedure informed by gold standard measures of autism
symptomatology (e.g. Autism Diagnostic Observation Schedule), developmental
measures and clinical judgment (Chawarska, Klin, Paul, & Volkmar, 2007). Instability in
ASD diagnoses presents in individuals who display milder features or inconclusive
presentations at 2 years old (Guthrie, Swineford, Nottke, & Wetherby, 2013). In a sample
of 418 high risk infant siblings of children with ASD assessed at 18, 24 and 36 months,
diagnostic stability at 24 months was 82% (Ozonoff et al., 2015). However, when the
sample was followed to age 3, 41% of the sample who met diagnostic criteria for ASD at
3 years old were determined to have been false negatives at the 24 month visit (Ozonoff
et al., 2015). Early false negatives were found to be behaviorally atypical at 24 months
(e.g., developmental delays, presence of autism symptomatology), however, their
presentation was not yet clear enough to meet diagnostic criteria for ASD. Taken
together, this research suggests that diagnostic stability in toddlers with nsASD is
dependent on clarity of the clinical presentation, which may not occur until 3 years of age
or later, highlighting the need for the monitoring of autism symptomatology into the third
year of life and beyond. Also, evidence suggests when instability occurs, it more often
represents false negatives at a young age than false positives.
Within the FXS literature, less is known about diagnostic stability across early
childhood with no published studies using a CBE process to inform diagnosis of ASD.
Research into the stability of ASD diagnoses and symptomatology in FXS to date has
largely relied on diagnostic categorizations determined by measure cutoffs, instead of
clinician judgment. Hernandes and colleagues (2009) used the ADI-R, a parent interview
5

about lifetime autism symptomatology, to inform diagnoses of ASD in a sample of 56
males with FXS, who had a mean age of 56 months at baseline. They reported general
diagnostic stability (68%) when participants were tested over the course of 3 years, with
far less stability in individuals with milder symptomatology (21%). At the symptom
level, the two diagnostic groups became less differentiated over the course of the study;
participants in the FXS+ASD group evidenced a reduction in autism symptomatology
while those with FXS-noASD, showed an increase in autism symptoms.
In a slightly older sample of 65 children with FXS (31 male, 34 female), ages 811 years, Lee and colleagues (Lee et al., 2016) used the ADOS to report diagnostic
stability and symptom change over time across 2 visits that were on average 2.5 years
apart. Across the 2.5 years, the percentage of male participants meeting criteria for ASD
increased from 54% to 80%, with most of the increasing impairment found in the social
communication domain. Rates of ASD were remarkably stable in the female participants,
which were reported to be 41.5% at time 1, and 41.2% at time 2. The study did not report
if any participants meeting criteria for ASD at time 1 failed to meet criteria at time 2, so
exact stability estimates are unknown.
In the largest longitudinal study to date (n=116), Hatton and colleagues (2006)
examined Childhood Autism Rating Scales (CARS-2, Schopler, Reichler, & Renner,
2002) total scores in a sample of 1.5 to 15 year olds. The CARS-2 is a clinician rated
measure that is completed after an observation and interactions with a child to rate
symptoms of ASD. It provides clinical categorizations into three groups based on raw
score totals; non-autistic, mild-to-moderate autistic behaviors and severe autistic
behaviors. The CARS-2 is considered to be a screener for ASD symptoms and is not a
6

diagnostic tool unless used in conjunction with other measures. When examining raw
scores over time, the authors reported an average increase of 2 points over 10 years.
Using the clinical categorizations provided by the CARS-2, the authors reported that
about 54% of the participants maintained their diagnostic category throughout the course
of the study, with 13% evidencing decreasing symptomatology and 33% evidencing
increases. Taken together, these studies suggest ASD symptom stability rates of 50-70%
within FXS. However, inferences about the diagnostic stability of clinical diagnoses of
ASD within FXS are limited due to the reliance on the use of measure cutoffs to create
diagnostic groups, rather than clinical decision making, in most current published work.
A more recent series of studies has emerged examining the stability of autism
features in infants with FXS. One of these studies used a case study approach to compare
8 participants between 9-24 months of age with FXS+ASD and FXS-noASD outcomes at
24 months of age (Hogan et al., 2017). Although the sample size was small, comparisons
suggested that autism symptomatology as measured by the Autism Observation Scale for
Infants (AOSI, Bryson, Zwaigenbaum, McDermott, Rombough, & Brian, 2008)
decreased in all participants between 9 and 12 months of age, with lower mean scores for
the participants in the FXS-noASD group. In a complementary study, similar patterns
were found in consistency of autism symptomatology between the 12 and 24 month time
points, in that infants with ADOS scores above diagnostic cutoffs at 24 months evidenced
higher AOSI scores at 12 months of age, than those who did not meet ADOS diagnostic
cutoffs at 24 months (Roberts, Tonnsen, McCary, Caravella, & Shinkareva, 2016). These
papers are important additions to the literature, in that they are the first to begin to
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explore autism symptomatology and stability in infants with FXS syndrome, when autism
symptoms often first emerge.
Taken together, these studies suggest variability in autism symptomatology across
development in young males with FXS, leading to inconsistent reports of diagnostic
stability. This variability may reflect the dynamic nature of development suggesting that
symptoms of ASD vary across time in individuals with FXS as other development
processes are occurring, such as increases in language/communication abilities or
increasing social demands. However, the significant variability in measurement tools and
diagnostic practices (i.e. measure cutoffs vs. clinician judgment) may also be contributing
to the inconsistent findings. Lastly, change in autism symptomatology in individuals with
FXS may be subtle throughout development and therefore poorly captured by measures
designed to produce categorical outcomes.
Challenges measuring change in autism symptomatology over time is not a
unique problem in FXS research (Anagnostou et al., 2015). Studies examining change in
core autism symptomatology in nsASD are also limited given that the gold standard
measures used in many studies such as the ADOS or ADI-R are diagnostic measures,
with limited score ranges that are intended to measure presence or absence of ASD
symptoms. A new measure, the Brief Observation of Social Communication Change
(BOSCC, Grzadzinski et al., 2016) has been designed specifically to address these
limitations in the ability to detect subtle change in autism symptomatology over time in
current commonly used measures. The BOSCC measures many of the core features
identified on the ADOS and ADI-R, however the coding ranges allow for greater
variability, allowing for detections of subtler changes. Currently, two studies using the
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BOSCC have been published; a paper examining the psychometric properties of the
BOSCC (Grzadzinski et al., 2016) and a paper examining ASD symptom change
following an early intervention program in 21 children with nsASD (Kitzerow, Teufel,
Wilker, & Freitag, 2016). In both studies, changes in BOSCC scores were detected with
small to medium effect sizes in as little as 6 months to 1 year, suggesting that the measure
is robust to detecting findings over short periods of time, and in small samples (n = 21;
Kitzerow et al., 2016).
Current Limitations
Across this body of work significant inconsistencies are present in the measures
used to quantify change in autism symptomatology, which make comparisons across
studies challenging. This is especially difficult given that some are parent report
measures while others are based on trained clinician observations. Additionally, all
measures reported (e.g. CARS-2, ADOS, ADI-R, AOSI), were not developed to measure
change, making clinically significant change harder to identify. For example, Hatton and
colleagues (Hatton et al., 2006) finding that CARS-2 scores increased 2 points over 10
years may have limited functional significance. Given that ASD is theoretically a lifelong
condition, this small change in total score over a 10-year period may instead reflect
reliability.
Other commonly used measures, such as the ADOS and ADI, are diagnostic tools
that are not sensitive enough to capture change over short periods of time (Anagnostou et
al., 2015; Grzadzinski et al., 2016). Given the diagnostic intention of these tools, some
items are considered to be “low threshold”, in that if the symptom is present, it is coded.
This approach, similar to a “present” or “absence” rating, it is not designed to
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differentiate nuances in autism symptomatology that may be expected to change
gradually over time. This is in contrast to the design of the BOSCC, which includes a
greater scoring range (0-5 vs. 0-3) and the ability to capture subtleties in the frequency
and quality of social communication behaviors and restricted interests/repetitive
behaviors. Additionally, the commonly used practice of using the ADOS or ADI to both
create the groups of interest (i.e., FXS+ASD vs FXS-noASD) and measure differences
(i.e., how do these groups differ on ASD symptoms as measured by the ADOS?), is
inherently flawed in the circular nature of these questions (i.e., if the ADOS was used to
differentiate the groups of interest, we would expect the groups to be different on the
ADOS). Therefore, a tool such as the BOSCC, which measures related but not identical
constructs to gold standard diagnostic tools of ASD, reduces the consequences of the
previously described practice.
The Present Study
The present study aims to address these gaps by utilizing a new measure designed
to capture change in autism symptomatology in a sample of 2 to 6-year-old males with
FXS. The BOSCC has been designed specifically to address limitations of current
measures’ ability to accurately measure change in core features of autism. Additionally,
predictors of these trajectories will be examined to determine both risk and protective
factors of the development of impairing autism symptomatology within FXS. By looking
at a range of predictors that have been previously identified as being related to co-morbid
autism symptomatology in FXS, we aim to identify risk factors that may be important
targets for intervention to improve functioning in young children with FXS. Lastly, this
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study aims to add to the literature by examining trajectories based on diagnostic stability
patterns, rather than using a single diagnostic timepoint to determine grouping status.
The present study aims to address the following research questions:
1) Do patterns of change in autism symptomatology differ in young males with FXS
dependent on their CBE diagnosis of ASD, and the stability of that diagnosis?
a. We hypothesize that children with FXS who have a CBE diagnosis of
ASD will show increasing ASD symptom severity over time, while
participants with FXS who do not have ASD will show minimal change in
the severity of ASD symptomology.
2) Do cognitive and language functioning in males with FXS predict change in
autism symptomatology over time?
a. Consistent with previous literature, we hypothesize that lower cognitive
and language functioning will be predictive of increasing autism symptom
severity.
Methods
Participants
This study included 28 males with FXS assessed between the ages of 2-8 years.
Females were excluded from the analysis because of small sample available for analysis
(n=11), with only 1 female meeting diagnostic criteria for ASD. Each participant had at
least 2 diagnostic assessments using the ADOS-2. The participants are drawn from a
larger ongoing longitudinal study, herein referred to as the “parent study”, measuring the
developmental trajectories of infants and preschool age children with FXS. Inclusion
criteria for the study included gestational age >36 weeks, English as the primary language
11

in the home and no other known medical conditions. Participants were recruited primarily
from research and medical sites, as well as social media sites, specializing in FXS.
The initial parent study measured the development of autism symptomatology in
infants with FXS (R01MH90194, PI: Roberts). Participants in this study were seen at 9,
12 and 24 months with a diagnostic assessment for ASD completed at the 24-month time
point. The subsequent renewal of this study allowed for the continued longitudinal
examination of the development of ASD in these participants through the preschool years
with diagnostic assessments for ASD targeted annually at 3, 4 and 5 years-of-age.
Therefore, the majority of participants had their first ASD diagnostic assessment at 24
months-old and follow up assessments at 3, 4 or 5 years-of-age. There was variability in
the number of assessments and in the age at which assessments occurred, however, given
the age of participants at onset of the study renewal and inclusion of a handful of
participants who were recruited for enrollment starting at 4 or 5 years-of-age. For
inclusion in the present study, participants were required to have at least 2 video recorded
diagnostic assessments which included the Autism Diagnostic Observation Schedule-2.
Measures
Brief Observation of Social Communication Change. The Brief Observation of
Social Communication Change (BOSCC, Lord et al., 2016) is a coding scheme designed
to measure change in autism symptomatology over time, when compared across 2 or
more time points. The BOSCC is coded based on 10-12 minutes of semi-structured play
between an adult and the target child. The BOSCC can be applied to a range of play
interactions that meet basic criteria by providing engaging and developmentally
appropriate materials and allowing the child to move freely around the room and explore
12

toys. Additionally, whatever setting and structure is selected for the initial observation
should be kept consistent for all future play sessions to which the BOSCC will be coded
and compared. The coding scheme consists of item level decisions trees that allow the
coder to answer a series of yes or no questions based on the behaviors in the observation.
Observations are split into two 6-minute segments, which are coded independently.
Fifteen items are coded, and items 1-12 are included in the total score. Total scores across
the two segments are then averaged to determine a participant’s total score on the
BOSCC. For the present study, the BOSCC coding scheme will be applied to video clips
selected from the participant’s ADOS-2 administrations. Video clips include the
following tasks from the ADOS-2 administrations; 3 minutes of Free Play, 3 minutes of
Bubble Play, 3 Minutes of Birthday Party or Bath Time and 3 Minutes of Balloon Play.
Alternative tasks are available to supplement (e.g. Snack, Response to Joint Attention) if
these tasks are less than 3 minutes in length. This collection of tasks and time lengths is
recommended by the authors and has been previously published by Kitzerow and
colleagues (Kitzerow et al., 2016). The first author of the present study has attended
research training on the coding of the BOSCC and has been given authorization to use it
for research purposes by the authors. According to measure use procedures, a team of
undergraduate research assistants were trained up to reliability standards with the first
author. To achieve reliability with the first author, coders must be within 1 point for more
than 80% of items on each coding segment and within 4 points on each segment total
score. To minimize coding drift, 20% of videos were coded by the first author and
another coder. Intraclass correlations were used to examine reliability of absolute
agreement, which was high (ICC = .911). BOSCC scores collected from the same child
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over time are compared to measure change. BOSCC scores will be the primary outcome
variable in the analyses.
Autism Diagnostic Observation Schedule-2. The Autism Diagnostic
Observation Schedule-2 (ADOS-2) is a standardized semi-structured play-based measure
used to assess behaviors consistent with a diagnosis of ASD. To administer the ADOS-2
within a research setting, examiners are required to attend research training and achieve
reliability in the administration and coding of the measure with group of certified trainers
at 80% reliability or become reliable with a research reliable examiner at the research
site. The ADOS-2 has 5 modules, which are administered based on an individual’s
chronological age and expressive language level. Throughout the ADOS-2, the examiner
provides opportunities for social interaction through a series of standardized behavioral
presses and activities. Some of these activities include free play, bubble play, balloon
play and imaginative play with a baby doll. Behaviors observed during these presses are
then coded on items measuring core features of ASD. Items are generally scored on a
scale of 0-3, with scores of 0 indicating a normative response or the absence of
atypicality, and a 3 indicating severe atypicality indicative of ASD. Items identified as
being the most specific to an autism diagnosis from each module are used to create an
algorithm score. A calibrated severity score can be derived from the algorithm score to
allow comparison across the ADOS modules. Participant scores on the ADOS-2 are used
to inform the CBE diagnostic procedures to determine the presence or absence of autism
at each visit. The ADOS-2 reports strong inter-rater reliability of 84% (Lord et al., 2012).
Within lab inter-rater reliability is calculated on a randomly selected sample of 20% of
administrations as part of the completed and ongoing studies. Current within lab inter14

rate reliability is 83.3%. As previously mentioned, segments of the videotaped ADOS-2
administrations will be used for the BOSCC coding scheme.
Mullen Scales of Early Learning. The Mullen Scales of Early Learning
(Mullen, 1995) is a standardized measure of development normed for young children
ages 0-60 month, that measures development in five areas; Gross Motor, Fine Motor,
Receptive Language, Expressive Language, and Visual Reception. Each domain produces
a raw score, which can be transformed into a T-Score and an Age Equivalent Score. TScores have a mean of 50 and a standard deviation of 10. A summary standard score, the
early learning composite (ELC), represents a composite score across all domains, with
the exclusion of Gross Motor. The ELC has a mean of 100, and standard deviation of 15.
Limitations exist in the use of T-scores for young children with developmental
disabilities due to floor effects. In this sample, in the domains of Visual Reception,
Expressive Language and Receptive Language, 46%, 54% and 64% were at the floor for
each domain respectively. Therefore, Mullen raw scores will be used in the analysis as
predictors of change scores on the BOSCC. The sum of the scores on the Expressive and
Receptive language domains will be used as a measure of language functioning. The
Visual Reception domain will be used as a measure cognitive functioning. Standard
scores will be used for describing the sample. Internal consistency for each of the skills
ranges from 0.75 to .08, and coefficients of test-retest reliability range from .70- .80
(Mullen, 1995).
Procedure
The USC institutional review board has approved all data collection procedures.
Assessments were conducted primarily in the participant’s homes, with occasional visits
15

at the Neurodevelopmental Disorders Lab at USC based on family preference.
Conducting visits in the participants’ homes allowed for decreased travel burden on
families with children with disabilities and supports increased ecological validity as it
removes the potential confound associated with a child’s adjustment to a novel laboratory
setting. Procedures followed in the home and lab settings were identical. Assessments
were conducted over the course of one to two days, in 3-4-hour sessions each day,
depending on the child’s age and attention span. Breaks were given throughout the
assessment as needed. Participants were compensated for participation. All in-person
measures were administered by research staff that included bachelors level research
assistants, graduate students and post-doctoral researchers. ADOSs were only
administered by staff who had achieved independent research reliability or within lab
reliability with a research reliable counterpart. For all assessments included in the present
study, a CBE diagnosis of ASD was determined at each time point by a team of at least 3
members of the research staff who were all research reliable on the ADOS, one of whom
was a licensed psychologist. The CBE procedure is standard in the field of ASD research
(Ozonoff et al., 2015). Data from the Mullen, Vineland Adaptive Behavior Scales, and
ADOS was integrated to determine whether a child met criteria for ASD. Additionally,
all research reliable staff on the ADOS attended monthly consensus coding meetings for
ongoing calibration of scoring.
Clinical best estimates of ASD were determined for participants at each time point
and the ADOS-2 videotapes were scored using the BOSCC. In addition to the evaluation
of ASD, global developmental delay was evaluated for each participant. All participants
in the study met criteria for global developmental delay at each assessment which is
16

consistent with the phenotype of young males with FXS. Therefore, all participants in
this study who meet criteria for ASD also have co-morbid developmental delay at all time
points.
Data Analytic Plan
At the time of analysis, 28 males with FXS had 2 or more ADOS administrations
available for BOSCC coding and were included in the analysis (total of 73 assessments,
range of 2-4 assessments per participant). Multilevel models are robust to variability in
the number of assessments. As an initial step, data were plotted longitudinally using
spaghetti plots. A linear pattern was evident, therefore linear models are used. Multilevel
models were used to examine change over time in BOSCC scores, specifying time as the
level 1 clustering variable, with individual variables entered at level 2. Across all models,
age was centered at 24 months, given that the majority of participants had their first time
point at 24 months. Therefore, intercepts are interpreted as the average BOSCC score at
24 months of age. Slopes will be interpreted as the average change in BOSCC scores per
month.
As an initial step, participants were grouped in terms of the stability of ASD
diagnoses. A stable diagnosis was defined as meeting or not meeting ASD diagnostic
criteria at all assessments while an unstable diagnosis was defined as meeting ASD
diagnostic criteria for one or more assessments but not across all assessments. In the total
sample, 54% percent had stable ASD positive diagnoses, 21% percent had stable ASD
negative diagnoses, 11% percent changed from an ASD positive diagnosis to an ASD
negative diagnosis, and 14% percent changed from an ASD negative diagnosis to an ASD
positive diagnosis. Thus, 75% demonstrated a stable positive or negative ASD diagnosis
17

and 25% demonstrated an unstable ASD diagnostic trajectory representing both initial
false positives and false negatives. Based on these diagnostic stability patterns,
participants were split into 4 groups: 1) stable ASD positive (Stable ASD; n= 15), 2)
stable ASD negative (Stable noASD; n= 6), 3) participants with an initial diagnosis of
noASD which changed to ASD (Unstable ASD; n=4), and 4) participants with an initial
diagnosis of ASD which changed to noASD (Unstable noASD; n =3). Fit statistics (e.g.,
AIC and BIC) for models using the diagnostic stability groups described previously were
compared to models that dichotomized diagnosis to ASD or noASD based on the
participants “outcome” diagnosis (i.e., their diagnosis at the last time point for the
participant in the study). The model using the diagnostic stability grouping structure
evidenced the best statistical fit and aligned with the theoretical interest of the study, and
previous work in nsASD where diagnostic stability has been examined (Ozonoff et al.,
2015). Therefore, to answer research question one, the stability diagnostic group was
entered into the model as a level 2-time invariant predictor, to determine how diagnostic
group impacts initial BOSCC scores at 24 months and change over time.
To answer research question two, raw scores on the Mullen were entered in the
model as level 2-time invariant predictors. Raw scores were selected from the
participants assessment closest to the age of 24 months (m = 32.5, range = 23-78
months). Raw scores for expressive and receptive language were highly correlated (r =
0.79), therefore they were combined (i.e., summed) to create one language variable. A
sum, rather than an average, was selected to create the composite language variable given
that scores across the two language domains do not share an equivalent scale (i.e., 6 raw
score points on the Expressive Language domain is not necessarily developmentally
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equivalent to 6 raw score points on the Receptive Language domain). Visual Reception
raw scores were used as a measure of early non-verbal cognitive functioning.
Results
First, ANOVA tests were run to determine if the groups differed on demographic
variables or predictor variables of interest. All means and standard deviations are
presented in Table 1. More participants in the Stable ASD and Unstable noASD groups
were older than 24 months at their first ADOS/BOSCC time point (2/3 in the Unstable
noASD group, and 4/15 in the Stable ASD group), however differences in mean ages
between groups were not found to be statistically significant. Additionally, no statistically
significant differences were found between groups on age at Mullen, Receptive Language
T-scores or Fine Motor T-scores. For the remaining domains, overall F-tests were
significant. Therefore, Tukey HSD post-hoc tests were run to determine where
differences lie between groups. Only significant post-hoc tests are reported. On the
Expressive Language domain, the Unstable ASD group scored 11 points higher than the
Stable ASD group (p = .015). On the Visual Reception domain, the Stable noASD group
scored 8 points higher than the Stable ASD group (p = .053). The Early Learning
Composite was lowest in the Stable ASD group, which was 9.31 points lower than the
Stable NoASD group (p = .000), 8.79 points lower than the Unstable ASD group (p =
.00), and 12.11 points lower that the Unstable noASD group (p = .000). Participants in
the Stable ASD group had an average ADOS calibrated severity score (CSS) of 8.6,
which was 6 points higher than the Stable NoASD group (p = .000), and 4 points higher
than the Unstable ASD group (p = .000). Additionally, the Unstable NoASD group had
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an average CSS score of 7.67, which was 5 points higher than the Stable NoASD group
(p = .000), and 3 points higher than the Unstable ASD group (p = .015).
A taxonomy approach to the multilevel modeling was taken to address the
proposed research questions (Singer, Willett, & Willett, 2003). Results of the series of
models are presented in Table 2. First, the unconditional means model and unconditional
growth model were run. The unconditional means model (Model A) produced an
intraclass correlation (ICC) of 67.33, suggesting that 67% of the variance in BOSCC
scores are attributable to differences among participants. Next, the unconditional growth
model, including age centered at 24 months, was run. Within-person variance declined
between Model A and Model B, producing a pseudo R2 of 0.38, suggesting that 38% of
the within-person variability is associated with the linear effect of time.
Next, diagnostic group was added to the model as a predictor of initial status (i.e.,
average BOSCC score at 24 months) and change over time (Model C). The Stable ASD
group was selected as the reference group. On average, participants in the Stable ASD
group had initial BOSCC scores of 31.64 (t = 14.40, p = 0.00). Participants in the Stable
NoASD group (b = -16.49, t = -4.20, p = 0.00), and Unstable ASD group (b = -9.86, t = 2.24, p = .034) both had lower initial BOSCC scores than the Stable ASD group. Initial
BOSCC scores did not differ between the Unstable NoASD group and the Stable ASD
group (b = 0.68, t = 0.10, p = .924). Slopes did not differ between the Stable ASD group
and the Stable NoASD or Unstable ASD groups. However, participants in the Unstable
NoASD group evidenced a negative slope (b = 0.42, t = -1.90, p = .065), suggesting that
their BOSCC scores decreased by 0.42 points per month, compared to the Stable ASD
group. These trajectories are displayed in Figure 1. Between person variance declined
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from Model B to Model C producing a pseudo R2 of 0.60, which suggests that 60% of the
variability in initial BOSCC scores is associated with diagnostic group.
To answer research question 2, additional models were run to examine the effects
of language and non-verbal cognitive ability on initial BOSCC scores and change over
time. Language was determined to be negatively related to initial BOSCC scores (b =0.49, t = -3.93, p = .001), but not change over time. Non-verbal cognitive ability was not
related to initial BOSCC scores or change over time. When non-verbal cognitive ability
was added to the model, language remained as a significant predictor, however model fit
declined (i.e., AIC and BIC estimates increased), so non-verbal ability was removed for
the final model. Variance estimates for Model D suggest that language accounts for an
additional 8% of the variability in initial BOSCC scores.
Discussion
This study examined the development of autism symptomatology over time in
young males with FXS, using a novel measure of social communication change.
Multilevel models were used to examine linear change based on diagnostic group,
including early language and non-verbal cognitive ability as predictors of initial BOSCC
scores and change over time. The data included in this study are drawn from a parent
study that is the first study to track the stability of the clinical best estimate diagnosis of
ASD in young children with FXS, beginning in toddlerhood (NIH R01MH90194, PI:
Roberts). Therefore, this study is the first to explore the longitudinal development of
autism symptomatology change in toddler and preschool aged children with FXS
accounting for instability in the diagnoses of ASD at the individual level. While limits
exist with this approach (i.e., namely, small sample sizes), the information gathered from
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this study is essential for furthering the understanding of the heterogeneity of autism
Participants comprised 4 groups, Stable ASD (54%), Stable NoASD (21%),
Unstable ASD (14%) and Unstable NoASD (11%). For those who received their first
diagnosis at 24 months (n=22), 77% had stable diagnostic trajectories and maintained the
diagnosis of either ASD or non-ASD across time. Of the 5 participants who displayed
ASD diagnostic instability, 1 was a false positive, and 4 were false negative. This
suggests that it is more likely for young males with FXS to be false negative than false
positive for ASD at 2 years old. This is consistent with patterns in nsASD work of a 5:1
false negative to false positive ratio (Ozonoff et al., 2015). At 24 months, 83% of
participants who received a diagnosis of ASD maintained that diagnosis across time
which is consistent with the nsASD literature, which reports a diagnostic stability of ASD
at 24 months of 82% (Ozonoff et al., 2015).
Our results suggest that there is significant variability in the presence and severity
of ASD symptomatology within the FXS phenotype at 24 months-of-age. This
variability can be partially explained by diagnostic categorization and stability of ASD.
As a group, young children with FXS who have early and stable diagnoses of ASD
throughout childhood display the most severe symptomatology, with symptom levels
remaining high and stable across time. In a seemingly parallel pattern, participants with
an early and stable diagnosis of FXS noASD, evidence much lower levels of autism
symptomatology at 24 months with symptoms remaining low and stable over time. This
finding is contradictory to the results published by Hernandes and colleagues (2009), who
reported that autism symptomatology across their two diagnostic groups (FXS+ASD and
FXS-noASD) became less differentiated across time. These contrasting findings may be
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attributable to differing methodologies across the studies in the measurement of autism
symptoms (i.e., BOSCC in the present study vs. ADI-R in the Hernandes study),
diagnostic categorization procedures (i.e., CBE in the present study vs. ADI-R cutoffs at
Time 1 in the Hernandes study), or their slightly older sample at Time 1 (i.e., 33 months
in the present study vs. 56 months in the Hernandes study). Additionally, Hernandes and
colleagues reported that 32% of participants in their sample changed diagnostic
categories over the course of the study, however their diagnostic grouping was based on
their Time 1 data. Therefore, their dichotomous approach subsumed participants with
instability in their diagnostic trajectories into the diagnostic group determined at their
initial visit. The findings presented in the current study may represent the trajectories for
more “pure” diagnostic groups of FXS+ASD and FXS-noASD, given that the Stable
ASD and Stable NoASD groups exclude participants who display diagnostic instability.
Compared to the Stable ASD group, participants in the Unstable ASD group had
initial BOSCC scores that were 10 points lower, however there were no measurable
differences in slopes. In theory, the UnstableASD group represents a group of males with
FXS whose early symptom presentation did not warrant a diagnosis of ASD, with
symptoms appearing more consistent with ASD over time (i.e., false negative cases).
Contrary to what was hypothesized, these participants’ BOSCC scores didn’t
significantly “worsen” with time, rather they follow a flat trajectory. Clinically, this
group may represent a group of males with FXS who exhibit a milder presentation of
ASD and whose symptoms of ASD are harder to distinguish from global developmental
delay in toddlerhood. The flat BOSCC trajectories would suggest that their diagnostic
instability may be influenced by clinician factors (e.g., a more conservative approach to
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diagnosing ASD in FXS in toddlerhood when the symptom presentation is less severe
and global developmental delay is present), rather than a result of a significant
“worsening” in symptom presentation with time.
This finding is distinct from what has been described in the nsASD literature,
where the “false negative” participants evidenced a worsening of autism symptomatology
over time. This worsening is hypothesized to represent the later emergence of ASD,
rather than clinician level variables or true misdiagnoses at earlier timepoints (Ozonoff et
al., 2015). While autism symptom trajectories appear to differ, the false negative groups
across the current study and the nsASD literature share a common feature of being
slightly higher functioning in language and cognitive abilities than those with early and
stable diagnoses of ASD.
The only group to display a declining slope (i.e., fewer ASD symptoms over time)
was the Unstable NoASD group. These participants are similar to participants described
as “false positives” in other work, who receive a diagnosis of ASD early on in
development, however they no longer meet criteria for ASD as they age. This group was
the minority of the sample, with only 3 participants falling into this group. Clinically,
these participants are important as they represent a group of children who appear to “get
better” with time, who may hold answers to effective interventions or protective factors
within the FXS phenotype. In contrast to false positive cases in the nsASD literature,
these children do not show a milder or “intermediate” presentation of ASD. Initial ADOS
severity scores for the Unstable NoASD group were 7.67, which is on the cusp between
moderate to high levels of ASD related symptoms and did not differ from the Stable ASD
group. However, these two groups did differ on global development, with the Unstable
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NoASD group scoring almost 1 standard deviation higher on a measure of broad
development at their initial time point, measured by the Mullen Early Learning
Composite.
In addition to understanding developmental trajectories of autism
symptomatology, this study aimed to discover predictors of early symptom presentation
and trajectory, with non-verbal cognitive functioning and language being the primary
domains of interest. Language and non-verbal cognitive impairment have long been
established as prominent features of the FXS phenotype, often developing at similar
levels (Abbeduto, Brady, & Kover, 2007). These delays complicate the diagnosis of
ASD in FXS given the need to differentiate global delays in development from a specific
social communication impairment consistent with ASD. For example, a clinician may
have trouble determining whether a lack of gesture use or poor integration of
communication forms (e.g., eye-contact, gestures, vocalizations) is the result of an
immature social communication system or an impaired one resulting from ASD. Given
this concern, clinicians may attribute autism symptomatology seen within FXS to
developmental delay, more broadly.
In this study, higher language scores at 24 months, predicted lower initial BOSCC
scores (i.e. less autism symptomatology), but not slopes over time. In contrast, non-verbal
cognitive ability was not predictive of initial BOSCC scores or slopes over time.
Therefore, early language abilities, but not non-verbal functioning, may serve as a
protective factor for children with FXS resulting in more robust and advanced social
communication abilities. Language abilities have also been found to predict ASD
symptom severity in adolescents with FXS, suggesting that this is a persistent
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relationship within the FXS+ASD phenotype (Abbeduto et al., 2019). This finding has
important implications for early intervention targets in young children with FXS, with
recommendations to focus on language development before 24 months as a possible
protective factor to the development of autism symptomatology.
Given that scoring on two BOSCC items includes vocalizations (i.e. vocalizations
directed to others, integration of vocal and non-vocal modes of communication), it is
prudent to consider whether the relationship between higher language abilities and
BOSCC scores may be influenced by these items. The current sample is not large enough
to conduct this type of analysis, however future research may consider examining if
overlap in the measurement of language on the Mullen and BOSCC is able to partially
explain this relationship. However, vocalizations need not be complex to receive credit
on the BOSCC, therefore it is unlikely that the relationship between language abilities
and initial BOSCC scores can be completely accounted for by these items.
While the variables of interest in this study accounted for a significant amount of
variance in this data, unexplained variance remains to be understood. Specifically, we
were unable to explain some of the variance associated with change over time in autism
symptomatology. Future work may choose to focus on time-varying predictors which
may be able to provide additional insight into predictors of individual growth trajectories.
This study presents important and novel findings to enhance the understanding of
autism symptom trajectories within the early developmental period in males with FXS.
Individuals with FXS and co-morbid ASD are at greater risk for more profound
impairment in language, cognition and adaptive skills, and require greater levels of
service to achieve optimal outcomes. The findings presented here inform not only
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possible surveillance and diagnostic practice of ASD in FXS, but also inform early
intervention recommendations. The vast majority (83%) of participants who received a
diagnosis of ASD at age 2, maintained this diagnosis over time. This finding supports the
clinical practice of screening for, evaluating, and diagnosing ASD within FXS as early as
age 2, should symptoms be clear and compelling. Additionally, clinicians should remain
vigilant and follow children whose presentation at 24 months is atypical, albeit milder
than FXS peers with more impaired cognitive and language abilities. This study
highlights that these individuals may not necessarily “get worse” over time or grow into a
diagnosis of ASD. Rather, a lack of improvement in social communication or a lack of
any clear reduction in autism symptomatology may be evidence of co-morbid ASD. It is
important to note that the clinicians in this study were highly experienced with both ASD
and FXS, and this level of expertise in unlikely to be present in all community settings
where families of young children with FXS may be seeking an evaluation for ASD. This
may increase the risk for diagnostic overshadowing in these settings, where clinicians
may be less likely to diagnose a co-morbid condition instead attributing behavioral
symptoms of ASD to the FXS phenotype.
Early language abilities, distinct from non-verbal abilities, were predictive of
BOSCC scores at 24 months with higher language scores being associated with lower
BOSCC scores. Language abilities at 24 months, however, did not make a child more or
less likely to have a declining or inclining slope. Given the longstanding knowledge of
language impairment in FXS, and the relationship identified between language and early
autism symptomatology in this study, language intervention should be prioritized as an
early intervention for young children with FXS.
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This study is limited by a few factors. Primarily, the small sample size. Fragile X
syndrome is a rare syndrome, making recruitment of large samples especially at young
ages, challenging. This sample capitalizes on longitudinal data from 28 males which
results in 73 data points providing more power to the analysis. Admittedly, the diagnostic
grouping structure (i.e., stability groups) results in very small samples for comparison.
However, this structure aligned with the theoretical questions of this study and resulted in
a better statistical fit than a dichotomous approach of FXS+ASD and FXS-noASD.
Future work should assess generalizability of the findings in a larger sample. Females
were intentionally excluded from this study given the significant heterogeneity within the
female FXS phenotype. Therefore, we must acknowledge that the results presented here
can only be generalized to young males with FXS.
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Table 1.1 Participant Demographics for FXS Males (n = 28)
Stable ASD

Stable noASD

Unstable

Unstable noASD

n = 15

n=6

ASD

n=3

n=4
ADOS-2/BOSCC1
Age in Months

35.15 (18.08)

25.63 (0.75)

24.77 (1.35)

43.32 (16.06)

8.6 (1.4)

2.33 (1.21)

3.75 (2.99)

7.67 (0.58)

30.63 (9.41)

15.08 (6.76)

20.25 (1.04)

25.50 (11.79)

Age in Months

29.15 (11.35)

25.65 (0.70)

24.57 (1.35)

39.21 (12.90)

ELC

52.33 (6.62)

60.83 (7.96)

59.75 (3.20)

63.33 (13.58)

Visual Reception T-Score

22.87 (5.11)

31.00 (7.21)

31.00 (2.58)

33.33 (11.55)

Exp. Language T-Score

22.53 (5.37)

28.00 (7.18)

34.00 (3.37)

30.33 (10.50)

Rec. Language T-Score

22.53 (6.52)

29.50 (12.71)

22.50 (3.00)

29.00 (8.54)

Fine Motor T-Score

21.47 (3.23)

24.33 (4.59)

22.75 (1.89)

25.00 (5.57)

ADOS CSS
BOSCC Total
Mullen2
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ADOS-2 Autism Diagnostic Observation Schedule, 2nd Edition, BOSCC Brief Observation of Social
Communication Change, CSS Calibrated Severity Score, Mullen Mullen Scales of Early Learning, ELC
Early Learning Composite
1
Data corresponds to the first ADOS available for coding
2
Data corresponds to the Mullen administered closest to the 24-month timepoint; standard scores are
presented.

Table 1.2 Results of a taxonomy of multilevel models for change in BOSCC scores over time
Initial Status

Rate of Change
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Variance
Components
Level 1
Level 2 (b/t
person)

Intercept
Stable noASD
Unstable ASD
Unstable
noASD
Language
Intercept
Stable noASD
Unstable ASD
Unstable
noASD
Within person
In initial status
In rate of
change

Pseudo R2
Model Fit
** p < .05, *p < .1

Within person
In initial status
AIC
BIC

Model A
25.80**
(1.94)
----

Model B
25.06** (2.16)

Model C
31.64** (2.20)

Model D
41.32** (3.07)

----

-16.49** (3.92)
-9.86** (4.40)
-0.68 (7.12)

-10.22** (4.07)
-4.80 (4.33)
11.45 (7.47)

------

-0.04 (0.06)
----

-0.07 (0.08)
-0.21 (0.23)
-0.00 (0.16)
-0.42* (0.23)

-0.49** (0.13)
0.12 (0.08)
-0.33 (0.22)
-0.04 (0.16)
-0.41* (0.22)

42.62 (6.52)
87.86 (9.37)

26.48 (5.14)
85.74 (9.25)

26.63 (5.16)
34.08 (5.84)

26.05 (5.10)
27.73 (5.27)

--

0.04 (0.21)

0.05 (0.22)

0.05 (0.22)

--534.07
540.90

0.38
-536.62
550.36

0.38
0.60
512.71
538.80

0.38
0.68
504.96
533.03

Stable ASD
Stable noASD
Unstable ASD
Unstable noASD

Figure 1.1 Uncontrolled effects of diagnostic stability group on BOSCC scores over
time
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CHAPTER 2
CROSS-SYNDROME CONTRASTS OF AUTISM SYMPTOMS IN
YOUNG CHILDREN: FRAGILE X, DOWN SYNDROME AND NONSYNDROMIC AUTISM
Autism spectrum disorder (ASD) is a developmental disorder that is characterized
by deficits in social communication and the presence of atypical restricted and repetitive
behaviors and interests (American Psychiatric Association, 2013). ASD is one of the
most common and impairing childhood conditions, with prevalence rates of about 1.5%
in the general population (Centers for Disease Control, 2014). Heritability of ASD is
estimated to be around 70-80% with more than 1000 identified risk genes as well as a
handful of single gene disorders that carry a high risk for developing ASD (Geschwind,
2011).
ASD is a heterogeneous disorder, with core impairments of social communication
and restricted and repetitive behaviors accompanied by a myriad of cognitive, language
and adaptive behavior presentations. One of the most impairing co-morbid features of
ASD is intellectual disability (ID), which occurs in approximately 37-55% of individuals
with ASD (Charman et al., 2017; Rivard, Terroux, Mercier, & Parent-Boursier, 2015).
The presence of ID in young children at risk for ASD can make diagnosing ASD more
complex, given that it requires diagnosticians to differentiate delays associated with ID
from those better explained by ASD (Matson & Shoemaker, 2009). Diagnostic
differentiations are also complicated by the overlap in symptomatology between ASD
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and ID including symptoms often thought to be classic features of ASD such as repetitive
behaviors and echolalia occurring commonly in individuals with ID more broadly
(Wallander, Dekker, & Koot, 2003). However, accurate and early diagnosis of the comorbidity of ASD and ID is essential, given that their co-occurrence causes individuals to
experience greater impairments and less optimal outcomes than individuals with either
condition in isolation.
Single-Gene Models of ASD
Single gene disorders account for about 1-2% of all ASD cases (Abrahams &
Geschwind, 2008). While mechanisms for impairment across the single-gene disorders
are varied (e.g. excess gene expression, protein deficit) consistency exists in the almost
universal ID present in many conditions. Therefore, single gene disorders are an excellent
model for studying the behavioral phenotype of ASD in individuals with ID. Fragile X
syndrome (FXS) and Down syndrome (DS) are two excellent models to examine these
relationships given that ID is nearly universal in both disorders, and they are relatively
common in the population at 1 in 5000 (Coffee et al., 2009) and 1 in 1500 (Kazemi,
Salehi, & Kheirollahi, 2016) respectively.
Autism Symptomatology in FXS
FXS is the most common form of inherited ID (Hagerman & Hagerman, 2002).
FXS results from a repeat expansion of the CGG sequence on the FMR1 gene on the X
chromosome. Repeats on the FMR1 gene that exceed 200 result in methylation of the
gene, which significantly reduces or eliminates production of Fragile X Mental
Retardation Protein (FMRP), which is essential for cognitive development. Females with
FXS are often less impaired than males with FXS due to the presence of a second X
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chromosome which will produce FMRP if it is unaffected by the FXS mutation
(Hagerman & Hagerman, 2002).
A significant body of work has been developed examining the relationship
between ASD and FXS. Consistent across these studies are findings that the rates of ASD
in FXS are high, with estimates ranging from 60-75% (Harris et al., 2008; Klusek,
Martin, & Losh, 2014). The presence of ASD in FXS results in greater impairment across
a range of domains including cognition (Bailey Jr, Hatton, Tassone, Skinner, & Taylor,
2001; Hogan et al., 2017; Kaufmann et al., 2004), adaptive behavior (Caravella &
Roberts, 2017; Hahn, Brady, Warren, & Fleming, 2015), language (Klusek et al., 2014),
motor skills (Bailey, Hatton, Mesibov, Ament, & Skinner, 2000) and social approach
behaviors (Roberts et al., 2019). There is consensus that features consistent with ASD are
commonly observed in individuals with FXS (Hagerman & Hagerman, 2002), however
there continues to be debate about the etiology of the symptoms, and whether or not they
constitute the presence of a true comorbidity of ASD or represent phenotypic features
associated with FXS. Evidence across biological and behavioral studies suggests that
symptoms of ASD in FXS may be behaviorally similar to non-syndromic ASD (nsASD),
however different patterns of strengths and weaknesses may emerge with time (Wolff et
al., 2012) that could be driven by unique brain mechanisms (Hazlett, Poe, Lightbody,
Gerig, Macfall, et al., 2009). These strengths in FXS and comorbid ASD (FXS+ASD) are
typically identified in the social domain, marked by increased frequency and quality of
social overtures even in those diagnosed with ASD (McDuffie, Thurman, Hagerman, &
Abbeduto, 2015; Wolff et al., 2012). However, evidence suggests that strengths in social
communication in FXS+ASD may not emerge until around the age of 4 of 5 (Wolff et al.,
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2012), with little differentiation between nsASD and FXS+ASD observed in the toddler
years (Hazlett, Poe, Lightbody, Gerig, Macfall, et al., 2009; Rogers, Wehner, &
Hagerman, 2001).
Longitudinal examinations of ASD symptomatology in individuals with
FXS+ASD suggest variability in the presentation of ASD symptomatology over time. In
infancy, ASD symptoms appear to remain elevated, albeit decreasing over time (Hogan et
al., 2017), followed developmentally by reports of both increasing (Hatton et al., 2006;
Lee, Martin, Berry-Kravis, & Losh, 2016) and decreasing (Hernandes et al., 2009) ASD
symptomatology in early childhood. This variability is intriguing and may be attributable
to the wide range of measures used to assess change in ASD symptomatology across
these studies, variability present in the methods used to determine ASD diagnostic status
(i.e. parent report vs. measure cutoffs vs. clinician judgment) or developmental effects
and age related changes in symptomatology.
ASD Symptomatology in DS
Down syndrome is the most common form of ID, caused by the presence of three
copies of the 21st chromosome, in either all or a portion of the body’s cells. DS occurs at
a rate of between 1 in 400 to 1 in 1500 and affects males and females similarly (Kazemi
et al., 2016). Three types of DS are possible: trisomy 21 (95%), translocation (4%) and
mosaicism (2%). Children with the mosaicism form of DS are often less severely
impaired than the 2 other types of DS because the third copy of chromosome 21 is not
present in all cells in the body (Papavassiliou, Charalsawadi, Rafferty, & Jackson-cook,
2014).
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Research into symptomatology and features of ASD in DS is significantly more
limited than in FXS. This may be partly attributable to the historically held belief that
individuals with DS “could not have” ASD because of the documented sociability in
many with the syndrome, with some hypothesizing that this high sociability may serve as
a protective factor against ASD for these individuals (Rasmussen, Borjesson, Elisabet, &
Gillber, 2001; Reilly, 2009). However, research has suggested that rates of ASD in DS
are elevated compared to the general population, ranging from 7-39% (Diguiseppi et al.,
2010; Hepburn, Philofsky, Fidler, & Rogers, 2008; Kent et al., 1999; Nærland, Bakke,
Storvik, Warner, & Howlin, 2017), and that the presence of comorbid DS and ASD
(DS+ASD) results in greater functional impairment (Diguiseppi et al., 2010; Dressler,
Perelli, Bozza, & Bargagna, 2011; Moore Channell et al., 2019).
Similar to young children with nsASD (Landa, 2008), research examining
individuals with DS+ASD suggests that parents report observing symptoms consistent
with ASD in infancy and toddlerhood and that their behavioral phenotype is distinct from
those with DS without ASD (DS-noASD) (Rasmussen et al., 2001). Despite symptoms
being present in infancy, most children with DS are not diagnosed with ASD until they
are between 6-14 years-of-age (Rasmussen et al., 2001) highlighting a significant missed
opportunity for targeted early intervention. Similar to findings in FXS, ASD
symptomatology may occur on a spectrum within DS, with some individuals meeting full
criteria while others show evidence of sub-threshold symptomatology. Social strengths,
including social reciprocity, using a range of facial expressions, imitation and eye-contact
have been identified in individuals with DS+ASD when contrasted to nsASD (Hepburn et
al., 2008; Starr, Berument, Tomlins, Papanikolaou, & Rutter, 2005; Warner, Howlin,
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Salomone, Moss, & Charman, 2017). Similarly, individuals with FXS have also been
noted to display social strengths when compared to individuals with nsASD, however
their strengths are identified in the areas of social smiling, showing and directing
attention, and sharing (McDuffie et al., 2015).
Studies comparing children with DS+ASD directly to nsASD have produced
inconsistent findings. In one of the largest studies examining school age children 6-15
years old, Warner and colleagues used the clinical cutoffs on the Social Communication
Questionnaire (SCQ) to define their DS+ASD group (n=183), and identified overall
lower SCQ scores in the DS+ASD group compared the nsASD group (n=189) (Warner et
al., 2017), with the greatest strengths in the social domain including imitation skills and
gesture use. Due to methodological limitations in this study (i.e., survey data), they were
unable to control for developmental or cognitive functioning between the nsASD and
DS+ASD groups.
In contrast, Moss and colleagues who also utilized the SCQ to measure ASD
symptomatology and to create their diagnostic groups, reported no significant differences
in the symptom profiles between the DS+ASD and nsASD groups (Moss, Richards,
Nelson, & Oliver, 2013). The Moss et al., study examined a much smaller sample (i.e., 17
DS+ASD, 17 nsASD), a much broader age range (4-62 years) and matched the groups on
overall ASD symptom severity (+/- 2 points on total SCQ). Therefore, it may be the case
that when overall symptom severity between nsASD and DS+ASD are similar,
differences in social communication strengths are not measurably different.
The literature reviewed thus far relies heavily on parent report screening tools to
determine diagnostic status of ASD within their DS samples. These findings are therefore
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limited due to possible biases in parent report of symptoms. More critically, however,
these tools are limited by their inability to take into consideration a participant’s
developmental level and how that may explain the presence or absence of certain social
communicative skills. Rather, they are blunt measures which when used with children
with ID, may not necessarily perform as designed. This is especially problematic in very
young children, or those with severe or profound ID (Starr et al., 2005).
There are only 2 published studies in DS research that utilize gold standard
diagnostic tools of ASD (e.g., Autism Diagnostic Observation Scheduled (ADOS) and
Autism Diagnostic Interview (ADI)) (Godfrey et al., 2019; Hepburn et al., 2008), with
only 1 using a clinical best estimate (CBE) procedure to examine the co-morbidity of
ASD within DS. Hepburn and colleagues (2008) assessed 20 children with DS
longitudinally, at 2 and 4 years old using a CBE procedure informed by the ADOS and
ADI, and reported a prevalence of 10%. Within the sample, 2 participants met CBE
criteria for ASD at age 2 and maintained that diagnoses at their follow up visit 2 years
later, with an observed worsening of symptoms. All participants without a co-morbid
diagnosis of ASD at their first visit, remained without ASD at their follow up
appointment. Thus, this study showed very high consistency in the diagnostic stability
across the preschool years both in those with and without diagnoses of ASD. Importantly,
the authors noted that if they had relied on ADOS scores alone, they would have
overidentified participants with DS+ASD as a number of the participants had scores on
the ADOS that fell in the ASD range but clinician view was that those features were
better accounted for by ID or other factors.
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In a more recent study, Godfrey and colleagues (2019) matched 66 participants
with nsASD to 22 participants with DS-noASD and 11 with DS+ASD on sex, age and
verbal mental age. Participants ranged in age from 30 months to 99 months. Diagnoses of
ASD were determined by clinical cutoffs on the ADOS, not CBE, and the ADI-R was
used as the outcome variable of interest. The study produced similar findings to the
Warner et al. study (2017) in that children with ASD+DS displayed less severe
symptomatology than the nsASD group in both the social communication and restricted
and repetitive behavior domains, however more severe symptomatology than the DSnoASD group.
Comparative Research Between FXS and DS
Currently, there are no studies comparing the development of autism
symptomatology in young children with FXS and DS. Comparative research between
FXS and DS has generally focused on language, cognitive development and adaptive
behavior suggesting unique patterns of strengths and weaknesses between the disorders
(Rice, Warren, & Betz, 2005; Valencia-naranjo & Robles-bello, 2017; Will, Caravella,
Hahn, Fidler, & Roberts, 2018). Although not directly comparing core features of ASD,
Abbeduto and colleagues compared theory of mind, a social cognitive construct often
found in deficit in individuals with ASD, in a sample of 11 to 23 year-olds with DS (n=
25) and FXS (n= 18) groupwise matched on chronological age, mental age and nonverbal
IQ (Abbeduto et al., 2001). Participants with DS were found to have greater impairment
in theory of mind functioning than individuals with FXS who performed similarly to the
typically developing control group. This finding is surprising given that rates of ASD are
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higher in FXS than DS, and theory of mind deficits are often seen in individuals with
ASD.
Taken together, these bodies of research suggest that individuals with some forms
of syndromic ASD (i.e. FXS and DS) may evidence preservation of skills in the social
communication domain that are not typically seen in individuals with nsASD, with
possible distinct profiles between the two syndromes. It is unknown, however, when
these differences emerge or if they are consistent over time. Only one study has examined
the longitudinal development of autism symptomatology in DS, and no work has
compared the development of autism symptomatology beginning in toddlerhood, in
individuals with FXS and DS.
Comparing developmental trajectories of autism symptomatology across these
etiologically distinct, but high-risk groups, is important to determine symptom overlap
and divergence to inform the clinical phenotype of ASD in single gene disorders. Across
both bodies of work, concern exists in the potential overidentification of ASD, given
almost universal ID and possible overlap in symptoms. Indeed, concerns also exist about
the bias to underdiagnose ASD in syndromic groups, known as diagnostic
overshadowing, (Jopp & Keys, 2001), which can result in missed access to specialized
services when they are needed.
While behavioral phenotypes of DS and FXS may overlap with nsASD, evidence
suggests that identifying specific ASD phenotypes within single gene disorders is critical
to providing treatment that targets possible underlying impairments (e.g., attention,
anxiety, cognitive function, social amotivation) that give rise to the behavioral phenotype
of ASD, which may be distinct from nsASD (Glennon, Karmiloff-Smith, & Thomas,
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2017). Understanding how these symptoms develop over time will provide important
insight into the symptom presentation of ASD in high-risk syndrome groups that can
inform screening and diagnostic practices and targets for intervention.
The Present Study
To our knowledge, there is no published literature comparing early autism
symptom trajectories in children with FXS, DS and nsASD. Given this gap in the
literature, this study aims to present preliminary findings from a pilot sample of 2-4-yearold children with FXS, DS and nASD, measured longitudinally. While expansion of this
sample is ongoing and will be used for a complete analysis and interpretation, this initial
exploration provides insight into possible differences between groups in autism
symptomatology at 24 months. Additionally, patterns of symptom trajectories will be
examined graphically, and initial hypothesis will be drawn to inform the larger study that
will be built upon findings from this initial pilot study. Specifically, this pilot study will
report rates of clinical best estimate diagnosis of ASD in a pilot sample of males with DS
and FXS, and compare FXS, DS and nsASD groups with respect to, 1) BOSCC scores at
24 months and 2) trajectories of autism symptoms (i.e., measured by the BOSCC) from
2-4 years.
Methods
Participants
The sample included 32 male participants aged 2-4, 17 FXS, 10 DS, and 5
nsASD. Participants each had between 2 and 3 assessments, with a total of 74
assessments in the sample (38 FXS, 25. DS, 11 nsASD). Participants were drawn from a
larger longitudinal study (R01MH90194) examining the early developmental trajectories
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of children with FXS compared to children at high and low risk of developing ASD (e.g.,
low risk controls, and infant siblings of children with ASD). A supplemental study
allowed for the addition of a pilot sample of infants with DS, to serve as a mental age
match to the FXS sample. Participants with FXS all had full mutation FXS, confirmed by
genetic report. The nsASD group includes participants from the low risk and high risk
ASIB groups diagnosed with ASD at their 24-month visit, where a genetic syndrome was
rules out. To reduce variability due to differences in cognitive functioning, all nsASD
participants were required to show developmental delays, measured by an Early Learning
Composite less than 85 on the Mullen Scales of Early Learning. The DS group was
confirmed by genetic report; 9 had Trisomy 21 and 1 had mosaicism. To be included in
the current study, participants needed to have at least 2 comprehensive diagnostic
assessments that included an ADOS, with the first occurring no later than 36 months of
age. Data was only included for assessments that occurred at ages 2, 3 and 4 years old,
given that this was the available range for the DS participants.
Exclusionary criteria for all participants included gestational age less than 37
weeks, a language other than English as the primary language in the home, and female
sex. Females were excluded because of the significant heterogeneity within the female
FXS phenotype, and the inability to account for that variability in such small pilot
samples.
Procedure
The USC Institutional Review Board approved all studies from which data will be
drawn for the present. As part of the parent study, participants were seen at 24 months for
a comprehensive diagnostic assessment for ASD. Through a renewal of the parent study,
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participants were seen annually through the age of 5 with recurrent annual comprehensive
evaluations. Variability in the number of participants assessed at each time point occurred
based on the time between a participants’ completion of the initial study (i.e., at 24
months) and the funding of the renewal. For some, this resulted in a missed
comprehensive evaluation at 36 months (n = 6).
Visits for the parent study were primarily conducted in the participant’s homes, to
minimize travel burdens for families with children with disabilities and to reduce effects
due to novelty of the research lab. When convenient for the family, assessments were
conducted at the Neurodevelopmental Disorders Lab at USC. At each assessment a
standard battery was completed. A CBE diagnosis of ASD (Ozonoff et al., 2015) was
determined at each evaluation by a team of at least 3 members of the research staff who
were all research reliable on the ADOS, one of whom was a licensed psychologist. All
available clinical information including the Mullen Scales of Early Leaning, Vineland
Adaptive Behavior Scales and the Autism Diagnostic Observation Schedule, were used to
determine whether the child met criteria for a diagnosis of ASD.
Measures
Autism Diagnostic Observation Schedule-2. The Autism Diagnostic Observation
Schedule-2 (ADOS-2) is a standardized semi-structured play-based measure used to
observe behaviors consistent with a diagnosis of autism spectrum disorder. The ADOS-2
has 5 modules (i.e. Toddler, Modules 1-4), which are administered based on an
individual’s chronological age and expressive language level. Items are generally scored
on a scale of 0-3, with scores of 0 indicating a normative response or the absence of
atypicality, and a 3 indicating severe atypicality. Items identified as being the most
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specific to an autism diagnosis from each module are used to create an algorithm score.
To allow for comparison across modules, algorithm scores can be converted to a
calibrated severity score, which fall on the same scale, 0-10, across all modules. The
ADOS-2 reports strong inter-rater reliability of 84% (Lord et al., 2012). Within lab interrater reliability is maintained above 80%. In the present study, the ADOS was used for
two purposes. First, the ADOS was used to inform the CBE diagnosis of ASD in all
groups. Second, video clips of tasks within the ADOS were coded using the Brief
Observation of Social Communication Change (described below).
Brief Observation of Social Communication Change. The Brief Observation of
Social Communication Change (BOSCC, Grzadzinski et al., 2016) is a coding scheme
designed to measure change in autism symptomatology over time in individuals with
minimal language, when compared across 2 or more time points. The BOSCC is coded
based on 10-12 minutes of semi-structured play between an adult and the child being
assessed. The BOSCC can be applied to a range of play interactions, however they must
include developmentally appropriate play and toy selection. The child must also be
allowed to freely move around the room and explore toys. Additionally, whatever setting
and structure is selected for the initial observation should be kept consistent for all future
play sessions to which the BOSCC will be coded and compared. Fifteen decision trees
are used to derive codes based on behaviors observed during the session. Observations
are split into two 6-minute segments, which are coded independently then averaged to
determine a child’s total score on the BOSCC. For the present study, the BOSCC coding
scheme will be applied to video clips selected from the participant’s ADOS-2. Video
clips will include the following tasks from the ADOS-2 administrations; 3 minutes of
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Free Play, 3 minutes of Bubble Play, 3 Minutes of Birthday Party or Bath Time and 3
Minutes of Balloon Play. This collection of tasks and time lengths is recommended by
the authors and has been previously published on by Kitzerow and colleagues (Kitzerow,
Teufel, Wilker, & Freitag, 2016). The first author of the current study has attended
research training on the coding of the BOSCC and has been given authorization to use it
for research purposes by the authors. Consistent with measure use guidelines, a team of
undergraduate research assistants were trained to reliability standards with the first
author. To achieve reliability with the first author, coders must score within 1 point for
more than 80% of items on each coding segment and within 4 points on segment total
scores. This requirement was met for 3 consecutive videos before coders were able to
code independently. Additionally, approximately 20% of videos were coded for
reliability to minimize coding drift. Intraclass correlations were used to examine
reliability of absolute agreement, which was high (ICC = .911).
Mullen Scales of Early Learning. The Mullen Scales of Early Learning (Mullen,
(Mullen, 1995) is a standardized measure of development normed for young children
ages 0-60 months. The Mullen measures development across five domains; Gross Motor,
Fine Motor, Receptive Language, Expressive Language, and Visual Reception. A
summary standard score, the early learning composite (ELC) represents a composite
score across all domains, with the exclusion of gross motor. The ELC has a mean of 100,
and standard deviation of 15. The Mullen was administered by trained research staff.
Internal consistency for each of the skills ranges from 0.75 to .08, and coefficients of testretest reliability range from .70- .80 (Mullen, 1995). The Mullen ELC was used as
inclusionary for the nsASD group (i.e., nsASD participants needed to have an ELC < 85.)
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Data Analytic Plan
Given small samples, descriptive analysis and simple comparisons were utilized
in lieu of complex inferential models. BOSCC scores from the first time point were
compared across groups using an ANOVA and Tukey HSD post hoc tests. Tukey HSD
tests analyze all possible pairwise comparisons and provides p-values that are corrected
for multiple comparisons. Comparisons at 36 and 48 months were not conducted; due to
the smaller samples at 36 and 48 months, a repeated measures ANOVA was not
appropriate. Third, BOSCC change scores were calculated as: Last BOSCC Total – First
BOSCC Total / Time in Months Between Assessments. One sample T-tests were
conducted to determine if change scores differed from 0.
Results
Clinical Diagnoses of Autism within FXS and DS participants
Within the FXS group, 65% of participants (n=11) met CBE criteria for ASD.
One participant was a false negative for ASD at his 24-month visit and was diagnosed
with ASD at both subsequent visits (36 and 48 months). Therefore, he is included in the
FXS+ASD group for all comparisons. All other participants displayed stable diagnoses of
either FXS+ASD or FXS-noASD throughout the duration of their participation in the
study.
Within the DS group, 20% of participants (n = 2) met CBE criteria for ASD.
These two participants were false negatives at their 24-month visit and diagnosed with
ASD at subsequent visits. The remaining participants did not meet criteria for ASD at any
time during their participation in the study.
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Examination of BOSCC Means and Trajectories
All but 1 participant had their first available BOSCC at 24 months. Means,
standard deviations and sample sizes at each age point are presented in Table 2.1. A
Shapiro-Wilk’s tests of normality was conducted on BOSCC scores at each time point
and determined that BOSCC score distributions did not differ from normality at any time
point. An ANOVA comparing BOSCC means at 24 months identified differences across
groups, F(4,26) = 4.94, p = .004. Post hoc comparisons using a Tukey HSD test, which
produce p-values corrected for multiple comparisons, indicated that the FXS+ASD (M =
29.68) group scored higher than the DS-noASD group (M = 17.86, p = .021) and higher
than the FXS-noASD group (M = 15.08, p = .005) on BOSCC scores at 24 months. The
average BOSCC score in the nsASD group at 24 months was 25.6, which is not
statistically different than any of the comparison groups. The DS+ASD group had a
mean BOSCC score of 22, which was the lowest of all groups with a co-morbid diagnosis
of ASD, although this was not determined to be statistically different from any
comparison group.
Longitudinal trajectories of BOSCC data by group are presented in Figure 2.1.
Change scores for each group, which represented the average change in BOSCC score
per month, are presented in Table 2.1. One sample T-tests were used to compare change
scores to 0. Results of the T-tests suggest that change trajectories for each group are not
different than 0 (i.e., all groups evidence flat BOSCC trajectories). However, these results
are likely affected by the small sample sizes. Visual examination of individual growth
trajectories highlights the heterogeneity within each group, which may be not best
captured by group level means.
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Discussion
This study reports findings from a pilot cross-syndrome longitudinal study of
ASD symptom trajectories in toddlers and preschoolers with DS, FXS or nsASD. This
study has two primary contributions. First, these pilot data provide important information
to guide the design of a more systematic and large-scale study with additional
participants. Second, given that no study has been published to contrast ASD trajectories
across these syndromes, the findings are important to the field. Given the pilot nature of
this study, caution is taken with regard to conclusions and inferences with limitations on
generalizability recognized. As such, the patterns observed from the DS+ASD group will
be described, however conclusive inferences will not be made given the sample size.
At the diagnostic level, rates of syndromic ASD in this pilot sample were
consistent with rates reported in the literature across both the FXS and DS groups, at 65%
and 20% respectively. Interestingly, both participants in the DS sample were false
negatives for ASD at their 24 month visit and were not diagnosed with ASD until their 36
month assessment. In the only other study to conduct comprehensive assessments for
ASD longitudinally in the toddler years in a DS sample, both participants with DS+ASD
(n = 2) met criteria for ASD at 24 months and maintained this diagnosis over time
(Hepburn et al., 2008). Future research should aim to identify what factors (e.g.,
individual level vs. clinician factors) may lead to these patterns of ASD diagnostic
instability in DS, as they have significant implications for clinical practice in screening
and surveillance.
This study suggests that by 24 months, participants in the FXS+ASD group are
scoring highest on the BOSCC, with scores that are significantly higher than individuals
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in both syndrome groups without ASD (i.e., FXS-noASD and DS-noASD). This finding
aligns with the theoretical approach of a specific ASD phenotype within FXS, that is
distinct from FXS without co-morbid ASD. In contrast, the FXS+ASD group could not
be differentiated at 24 months from the DS+ASD and nsASD groups, suggesting that on
average, these groups show similar levels of autism symptomatology at 24 months. This
finding, if replicated in a larger sample, would suggest that toddlers with syndromic ASD
and nsASD show similar composite levels of autism symptomatology during the toddler
years. This lack of differentiation in autism symptomatology between FXS+ASD and
nsASD groups in the toddler years is consistent with previous research (Hazlett, Poe,
Lightbody, Gerig, MacFall, et al., 2009; Rogers et al., 2001).
Although participants with DS+ASD did not significantly differ from the nsASD
group, they also did not differ significantly from the DS-noASD group. The DS+ASD
group in this study display an intermediate autism symptom phenotype that falls between
the nsASD and DS-noASD group (i.e., nsASD > DS+ASD > DS-noASD), although these
differences did not rise to levels of statistical significance. However, this ASD symptom
severity gradient within DS is consistent with what has been observed in larger studies
(Godfrey et al., 2019; Warner et al., 2017). In contrast to the DS sample, participants in
the FXS sample were distinguishable by almost 16 points on the BOSCC at their 24month time point, based on their clinical diagnoses (i.e., FXS+ASD vs. FXS-noASD).
This difference suggests there may be a much stronger distinction between ASD
diagnostic groups within FXS, with more subtle differentiations in individuals with DS.
This possible contrasting finding between the two syndrome groups will need to be
replicated in a much larger sample.
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At conception, this study was focused on comparing ASD symptom change
trajectories across time between non-syndromic and syndromic forms of ASD. The
BOSCC was utilized due to its ability to capture small and clinically relevant changes
over a short period of time. In the present study, slopes across all groups could not be
differentiated from 0 at the mean level. However, visual examination of BOSCC
trajectories (Figure 2.1) highlights the variability in slopes that are most often non-zero.
At a sample level, group does appear to explain variance in total BOSCC scores,
evidenced by the descending pattern in mean trend lines plotted by group in Figure 2.1.
However, the within group variability in slopes is masked at the mean level. Identifying
predictors of within group variability will be essential to explaining and interpreting this
heterogeneity.
Limitations and Future Directions
While this pilot study presents a novel comparison of ASD symptom trajectories
in 2-4-year olds with nsASD, FXS and DS, it is limited by the small samples, and
therefore generalizability is not yet possible. Since the inception of this pilot study, data
collection across all three groups has continued through the parent study. Therefore, a
follow up analysis is planned on a larger sample of participants, that is projected to
include: 25 participants with nsASD with developmental delay, 16 participants with DS,
and 21 FXS. The expanded sample will take advantage of multilevel models of change,
which are robust to uneven time points, which are present in this dataset.
Prospective research interested in examining the development of autism
symptomatology in young children with DS is inherently challenged by the relatively low
prevalence rates of ASD within DS. With reported prevalence estimates ranging from 750

39%, studies aiming for an outcome group of participants with DS+ASD need to enroll
somewhere between 65 – 350 participants, to end up with a modest sample size of 25
participants. This sample size challenge is evident in the two studies that used gold
standard in person diagnostic assessment of ASD, which included 2 (Hepburn et al.,
2008) and 11 participants (Godfrey et al., 2019) with DS+ASD respectively.
This recruitment challenge is shared by researchers who prospectively study
autism infant siblings at risk for developing ASD (ASIBs), where prevalence rates of
ASD are similar, at approximately 20% (Ozonoff et al., 2011). To address this challenge
in ASIB research, collaboration across sites and consortia (e.g., Baby Siblings Research
Consortium, Infant Brain Imaging Study) are capitalized upon to produce large samples
of children with outcome diagnoses of ASD. A recently launched NIH-Wide initiative
“INCLUDE (Investigation of Co-occurring conditions across the Lifespan to Understand
Down syndromE)”, lists ASD as a critical co-occurring condition that will be a target of
this initiative. Hopefully, through targeted funding and collaborative research efforts,
larger samples can be attained so that these important questions can be investigated to
guide screening, diagnostic and treatment efforts to improve outcomes for individuals
with DS and comorbid ASD.

51

Table 2.1 Mean BOSCC scores by group across time

FXS

24 months

DS

Non-Syndromic

FXS+ASD
n = 11

FXS-noASD
n=6

DS+ASD
n=2

DS-noASD
n =8

nsASD
n=5

29.68 (9.42) *+

15.08 (6.76)*

22.00 (4.24)

17.86 (5.77)+

25.6 (4.97)

(n = 7)
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36 months

32.71 (7.99)
(n = 7)

12.6 (4.85)
(n = 5)

21.25 (4.60)
(n = 2)

15.25 (5.94)
(n = 8)

26.75 (7.44)
(n = 4)

48 months

33.5 (7.26)
(n = 7)

13.75 (5.30)
(n = 2)

23.5 (--)
(n = 1)

15.1 (8.93)
(n = 5)

20.5 (9.90)
(n = 2)

Average change
score per month

0.23 (0.50)

-0.05 (0.35)

-0.24 (0.62)

-0.07 (0.38)

-0.08 (0.35)

*FXS+ASD > FXS-noASD
+
FXS+ASD > DS-noASD
FXS, Fragile X syndrome; DS, Down syndrome; ASD, autism spectrum disorder; nsASD, non-syndromic autism spectrum
disorder; BOSCC, Brief Observation of Social Communication Change
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Figure 2.1 Individual spaghetti plots
of BOSCC total score trajectories between
groups
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